Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.59 |
| ▸ | TUBB | P07437 | 1/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882020 | 0.90 | KDM4E (0.81) | KDM4EMEN1KMT2AHPGDHTT | |
| SCHEMBL15868699 | 0.89 | KDM4E (0.79) | KDM4EMEN1KMT2AHPGDHTT | |
| SCHEMBL30897563 | 0.81 | MEN1 (0.69) | KDM4EMEN1KMT2AHPGDHTT | |
| SCHEMBL3427648 | 0.79 | TUBB4A (0.68) | KDM4EMEN1KMT2AHPGDHTT | |
| SCHEMBL940853 | 0.79 | KDM4E (0.65) | KDM4EMEN1KMT2AHPGDHTT | |
| SCHEMBL2882593 | 0.79 | KDM4E (0.65) | KDM4EMEN1KMT2AHPGDHTT | |
| SCHEMBL6237719 | 0.79 | KDM4E (0.69) | KDM4EMEN1KMT2AHPGDHTT | |
| SCHEMBL14259277 | 0.79 | PRKD1 (0.66) | KDM4EMEN1KMT2AHPGDHTT | |
| SCHEMBL6241086 | 0.79 | KDM4E (1.00) | KDM4EMEN1KMT2AHPGDHTT | |
| SCHEMBL1655185 | 0.79 | PRKD1 (0.84) | KDM4EMEN1KMT2AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818724-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-11-13 | — | — | CN | disclosed |
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-2003129-B1 | 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| EP-2003129-B1 | 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9505785-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| EP-2003129-A1 | 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-17 | — | — | EP | disclosed |
| EP-2003129-A1 | 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-17 | — | — | EP | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20050143371-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005009370-A2 | BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| US-4994477-A | Hypotensive agents | ABBOTT LABORATORIES (US) | 1991-02-19 | — | — | US | disclosed |
| US-4472399-A | Indolo[2',3';3,4]pyrido[2,1-b]quinazoline-5-ones, a process for the preparation thereof, and diuretic compositions and methods using them | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1984-09-18 | — | — | US | disclosed |
| US-4252803-A | HYPOTENSIVE AGENTS, ANALGESICS | GLAXO GROUP LIMITED (GB) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | KDM4E 1947/4885MEN1 1063/4885KMT2A 500/4885 |
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | KDM4E 1408/4885MEN1 2146/4885KMT2A 3182/4885 |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | KDM4E 3424/4885MEN1 1017/4885KMT2A 2539/4885 |
| US-20050143371-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAP4K2, MAPKAPK2, MAP3K2 | KDM4E 2254/4885MEN1 1848/4885KMT2A 1193/4885 |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | KDM4E 1408/4885MEN1 2146/4885KMT2A 3182/4885 |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | KDM4E 1408/4885MEN1 2146/4885KMT2A 3182/4885 |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | KDM4E 1724/4885MEN1 2580/4885KMT2A 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.